MeiraGTx (MGTX) Projected to Post Quarterly Earnings on Tuesday

Key Points

• MeiraGTx will report Q1 2026 results before the market opens on Tuesday, May 12, with analysts forecasting EPS of ($0.43) and revenue of $17.003 million.
• The company previously surprised with a strong quarterly beat (EPS $0.19 vs. consensus -$0.60; revenue $75.36M vs. $3.87M) but still shows a negative return on equity and net margin, and analysts expect roughly -$2 EPS for the current and next fiscal year.
• Wall Street consensus is a Moderate Buy with an average price target of $25.67 and several firms lifting targets (up to $35), while insiders have sold about 145,661 shares in the past 90 days (insiders own 7.5% of the stock).

MeiraGTx (NASDAQ:MGTX - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.43) per share and revenue of $17.0030 million for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:00 AM ET.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last released its quarterly earnings results on Thursday, March 26th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.60) by $0.79. The business had revenue of $75.36 million during the quarter, compared to the consensus estimate of $3.87 million. MeiraGTx had a negative return on equity of 1,065.47% and a negative net margin of 140.31%. On average, analysts expect MeiraGTx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MeiraGTx Stock Up 0.8%

MGTX stock traded up $0.08 during mid-day trading on Tuesday, reaching $9.78. 176,712 shares of the company traded hands, compared to its average volume of 602,763. The stock has a market cap of $796.54 million, a price-to-earnings ratio of -6.91 and a beta of 1.23. MeiraGTx has a fifty-two week low of $4.55 and a fifty-two week high of $11.85. The firm's 50 day moving average price is $8.47 and its 200 day moving average price is $8.20.

Insider Transactions at MeiraGTx

In other news, insider Stuart Naylor sold 27,661 shares of the business's stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $9.36, for a total value of $258,906.96. Following the transaction, the insider owned 668,505 shares in the company, valued at $6,257,206.80. The trade was a 3.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Alexandria Forbes sold 62,000 shares of the business's stock in a transaction that occurred on Tuesday, March 24th. The stock was sold at an average price of $7.41, for a total value of $459,420.00. Following the completion of the transaction, the chief executive officer owned 1,449,695 shares in the company, valued at $10,742,239.95. The trade was a 4.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 145,661 shares of company stock worth $1,290,647 in the last 90 days. Insiders own 7.50% of the company's stock.

Hedge Funds Weigh In On MeiraGTx

Several institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its stake in MeiraGTx by 43.8% in the second quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company's stock valued at $31,000 after purchasing an additional 1,466 shares during the last quarter. Kennedy Capital Management LLC lifted its stake in MeiraGTx by 2.2% in the fourth quarter. Kennedy Capital Management LLC now owns 70,738 shares of the company's stock valued at $562,000 after purchasing an additional 1,495 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in MeiraGTx by 4.3% in the third quarter. Russell Investments Group Ltd. now owns 82,844 shares of the company's stock valued at $682,000 after purchasing an additional 3,452 shares during the last quarter. XTX Topco Ltd lifted its stake in MeiraGTx by 11.0% in the fourth quarter. XTX Topco Ltd now owns 38,030 shares of the company's stock valued at $302,000 after purchasing an additional 3,766 shares during the last quarter. Finally, Hsbc Holdings PLC lifted its stake in MeiraGTx by 24.3% in the fourth quarter. Hsbc Holdings PLC now owns 23,792 shares of the company's stock valued at $189,000 after purchasing an additional 4,649 shares during the last quarter. Hedge funds and other institutional investors own 67.48% of the company's stock.

Wall Street Analyst Weigh In

MGTX has been the subject of a number of analyst reports. Zacks Research upgraded MeiraGTx from a "strong sell" rating to a "hold" rating in a research note on Monday, March 9th. Bank of America boosted their target price on MeiraGTx from $14.00 to $16.00 and gave the stock a "buy" rating in a research note on Friday, March 27th. Royal Bank Of Canada boosted their target price on MeiraGTx from $16.00 to $24.00 and gave the stock an "outperform" rating in a research note on Friday, April 17th. Piper Sandler boosted their target price on MeiraGTx from $26.00 to $30.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 22nd. Finally, Chardan Capital restated a "buy" rating and issued a $35.00 target price on shares of MeiraGTx in a research note on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $25.67.

MeiraGTx Company Profile

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx's pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company's lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.